A cocktail of polypeptides for use in medicine wherein the cocktail of polypeptides is administered to a patient simultaneously, separately or sequentially with an immune checkpoint inhibitor, wherein the cocktail of polypeptides comprises: i) a polypeptide comprising a sequence of SEQ ID NO. 1 or an immunogenic fragment thereof comprising at least 12 amino acids or a sequence having at least 95% sequence identity to either the polypeptide or the immunogenic fragment; ii) a polypeptide comprising a sequence of SEQ. ID NO. 2 or an immunogenic fragment thereof comprising at least 12 amino acids or a sequence having at least 95% sequence identity to either the polypeptide or the immunogenic fragment; and iii) a polypeptide comprising a sequence of SEQ. ID NO. 3 or an immunogenic fragment thereof comprising at least 12 amino acids or a sequence having at least 95% sequence identity to either the polypeptide or the immunogenic fragment, wherein each polypeptide is less than 100 amino acids in length, and wherein the immune checkpoint inhibitor is at least one selected from the group consisting of: an anti-CTLA-4 antibody or an antigen-binding fragment thereof; an anti-PD-1 antibody or an antigen-binding fragment thereof; and/or an anti-PD-L1 antibody or an antigen-binding fragment thereof. wherein the cocktail of polypeptides comprises: i) a polypeptide comprising a sequence of SEQ ID NO. 1 or an immunogenic fragment thereof comprising at least 12 amino acids or a sequence having at least 95% sequence identity to either the polypeptide or the immunogenic fragment; ii) a polypeptide comprising a sequence of SEQ. ID NO. 2 or an immunogenic fragment thereof comprising at least 12 amino acids or a sequence having at least 95% sequence identity to either the polypeptide or the immunogenic fragment; and iii) a polypeptide comprising a sequence of SEQ. ID NO. 3 or an immunogenic fragment thereof comprising at least 12 amino acids or a sequence having at least 95% sequence identity to either the polypeptide or the immunogenic fragment, i) a polypeptide comprising a sequence of SEQ ID NO. 1 or an immunogenic fragment thereof comprising at least 12 amino acids or a sequence having at least 95% sequence identity to either the polypeptide or the immunogenic fragment; ii) a polypeptide comprising a sequence of SEQ. ID NO. 2 or an immunogenic fragment thereof comprising at least 12 amino acids or a sequence having at least 95% sequence identity to either the polypeptide or the immunogenic fragment; and iii) a polypeptide comprising a sequence of SEQ. ID NO. 3 or an immunogenic fragment thereof comprising at least 12 amino acids or a sequence having at least 95% sequence identity to either the polypeptide or the immunogenic fragment, wherein each polypeptide is less than 100 amino acids in length, and wherein the immune checkpoint inhibitor is at least one selected from the group consisting of: an anti-CTLA-4 antibody or an antigen-binding fragment thereof; an anti-PD-1 antibody or an antigen-binding fragment thereof; and/or an anti-PD-L1 antibody or an antigen-binding fragment thereof. an anti-CTLA-4 antibody or an antigen-binding fragment thereof; an anti-PD-1 antibody or an antigen-binding fragment thereof; and/or an anti-PD-L1 antibody or an antigen-binding fragment thereof.